Cardio Diagnostics integrates genetic and epigenetic biomarkers with AI analytics to deliver personalized cardiovascular insights through its clinical tests Epi+Gen CHD and PrecisionCHD and its population health offerings HeartRisk and CardioInnovate360. The platform’s blood-based testing suite targets risk across detection, prevention, management and therapeutic development stages.
Cardio Diagnostics’ platform combines proprietary genetic and epigenetic biomarkers with AI-driven analytics to generate personalized cardiovascular risk profiles from a single blood sample. This integrated approach enables early detection of disease markers and supports tailored intervention strategies based on individual molecular signatures.
The company offers two core clinical tests: Epi+Gen CHD for assessing coronary heart disease risk via combined genetic-epigenetic markers, and PrecisionCHD for guiding personalized disease management based on AI-enhanced risk stratification. Both tests aim to improve preventive care and therapeutic decision-making.
Cardio Diagnostics extends its technology through HeartRisk, a population health tool for community-level risk stratification, and CardioInnovate360, a biopharma solution supporting drug development and clinical trials. These offerings leverage the same AI-driven Core Technology to address cardiovascular disease from prevention to therapeutic innovation.
